Rozeman EA on Muck Rack

Rozeman EA

As seen in: Oxford University Press (OUP)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rozeman

Contact Rozeman, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma

|
By Rozeman EA, Lucas MW, Versluis JM, Blank CU
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (655) Issue with article?

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients - a single center experience

|
By Meerveld-Eggink AA, Rozeman EA, Lalezari FF
| Oxford University Press (OUP)
Background: Combination of T cell checkpoint blockade by CTLA-4- and PD-1-blockade is one of the most promising therapies in patients with advanced melanoma. It induces superior response rates as compared to single agent therapy, but at the cost of a high percentage of grade 3 and 4 adverse events (AEs).
Open in Who Shared Issue with article?

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience

|
By Meerveld-Eggink AA, Rozeman EA, Lalezari FF
| Oxford University Press (OUP)
Combination of T cell checkpoint blockade by CTLA-4- and PD-1-blockade is one of the most promising therapies in patients with advanced melanoma. It induces superior response rates when compared with single-agent therapy, but at the cost of a high percentage of grade 3 and 4 adverse events (AEs).
Open in Who Shared Issue with article?
See all 3 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Rozeman

Contact Rozeman, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified